Accuracy of 2-hydroxyglutarate quantification by short-echo proton-MRS at 3 T: A phantom study

Bertolino, Nicola; Marchionni, Chiara; Ghielmetti, F.; Burns, Brian; Finocchiaro, Gaetano; Anghileri, Elena; Bruzzone, Maria Grazia; Minati, Ludovico

doi:10.1016/j.ejmp.2014.03.002

Cited by 23 publications

(13 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…They attained 100% sensitivity and specificity for detection of the 15 IDH1-and IDH2-mutated tumors and noted a highly significant difference in the 1 H MR spectroscopically measured concentrations of 2-HG between the IDH-mutated and IDHwt tumors. In keeping with the results of Bertolino et al (75), they noted that this technique is superior to a short-echo sequence (78). Focusing on a separate aspect of the IDH1 mutation-induced catabolic changes, Chaumeil et al (79) used hyperpolarized carbon 13 ( 13 C) MR spectroscopy to detect the production of hyperpolarized [1-13 C] glutamate after injection of hyperpolarized [1-13 C] aketoglutarate.…”

Section: Conventional Imaging Featuresmentioning

confidence: 84%

Imaging Correlates of Adult Glioma Genotypes

2017

View full text Add to dashboard Cite

Primary brain tumors, most commonly gliomas, are histopathologically typed and graded as World Health Organization (WHO) grades I-IV according to increasing degrees of malignancy. These grades provide prognostic information and guidance on treatment such as radiation therapy and chemotherapy after surgery. Despite the confirmed value of the WHO grading system, results of a multitude of studies and prospective interventional trials now indicate that tumors with identical morphologic criteria can have highly different outcomes. Molecular markers can allow subtypes of tumors of the same morphologic type and WHO grade to be distinguished and are, therefore, of great interest in personalization of brain tumor treatment. Recent genomic-wide studies have resulted in a far more comprehensive understanding of the genomic alterations in gliomas and provide suggestions for a new molecularly based classification. Magnetic resonance (MR) imaging phenotypes can serve as noninvasive surrogates for tumor genotypes and can provide important information for diagnosis, prognosis, and, eventually, personalized treatment. The newly emerged field of radiogenomics allows specific MR imaging phenotypes to be linked with gene expression profiles. In this article, the authors review the conventional and advanced imaging features of three tumoral genotypes with prognostic and therapeutic consequences: (a) isocitrate dehydrogenase mutation; (b) the combined loss of the short arm of chromosome 1 and the long arm of chromosome 19, or 1p19q codeletion; and (c) methylguanine methyltransferase promoter methylation. RSNA, 2017.

show abstract

Section: Conventional Imaging Featuresmentioning

confidence: 84%

Imaging Correlates of Adult Glioma Genotypes

2017

View full text Add to dashboard Cite

show abstract

“…Water suppressed proton-magnetic resonance spectroscopy ( 1 H-MRS) has been explored to noninvasively detect 2-HG in gliomas for identification of IDH-1 gene mutation [ 80 , 81 ]. However, caution is currently warranted owing to the frequent false negative results and it remains to determine whether 2-HG levels could be qualified to serve as biomarkers for evaluating treatment response, tumor aggressiveness, and other malignant features [ 82 ]. Considering that IDH mutation status is associated with hypoxia induced factor-1 α , a driving factor in hypoxia-dependent angiogenesis, perfusion MRI may predict this genetic alteration indirectly.…”

Section: Applications Of Dce-mri and Dsc-mri In Gliomasmentioning

confidence: 99%

Clinical Applications of Contrast-Enhanced Perfusion MRI Techniques in Gliomas: Recent Advances and Current Challenges

Zhang

Liu

Tong

et al. 2017

Contrast Media & Molecular Imaging

108

View full text Add to dashboard Cite

Gliomas possess complex and heterogeneous vasculatures with abnormal hemodynamics. Despite considerable advances in diagnostic and therapeutic techniques for improving tumor management and patient care in recent years, the prognosis of malignant gliomas remains dismal. Perfusion-weighted magnetic resonance imaging techniques that could noninvasively provide superior information on vascular functionality have attracted much attention for evaluating brain tumors. However, nonconsensus imaging protocols and postprocessing analysis among different institutions impede their integration into standard-of-care imaging in clinic. And there have been very few studies providing a comprehensive evidence-based and systematic summary. This review first outlines the status of glioma theranostics and tumor-associated vascular pathology and then presents an overview of the principles of dynamic contrast-enhanced MRI (DCE-MRI) and dynamic susceptibility contrast-MRI (DSC-MRI), with emphasis on their recent clinical applications in gliomas including tumor grading, identification of molecular characteristics, differentiation of glioma from other brain tumors, treatment response assessment, and predicting prognosis. Current challenges and future perspectives are also highlighted.

show abstract

“…2-hydroxyglutarate (2-HG) can be detected on MR spectroscopy and is therefore considered to be the imaging hallmark of all IDH-mutant tumors [16]. However, reliable detection is challenging, and is possible only at some select centers with special MR spectroscopists on site [17][18][19].…”

Section: Radiological Featuresmentioning

confidence: 99%